Hepatitis B surface antigen (HBsAg) negative seroconversion (HBsAg < 0.05 IU/ml) is research hotspot in the field of hepatitis at this stage, and patients who achieve HBsAg negative seroconversion have significantly fewer liver-related complications. Presently, there are many studies with regard to HBsAg-negative seroconversion, but there are still relatively few indicators used in clinical practice to predict HBsAg-negative seroconversion. Low baseline HBsAg quantification and dynamic decline during treatment are currently recognized as the best indicators for predicting HBsAg-negative seroconversion. However, other factors such as viral genotype, elevated transaminases during treatment course, immune cell function and cytokine levels, and host factors can all influence HBsAg-negative seroconversion. This article reviews the relevant indicators and potential predictive factors for HBsAg-negative seroconversion.
乙型肝炎表面抗原（HBsAg）阴转（HBsAg < 0.05 IU/ml）是现阶段肝炎领域的研究热点，达到HBsAg阴转的患者其肝脏相关的并发症明显减少。目前关于HBsAg阴转的研究较多，但临床中用于预测HBsAg阴转的指标仍偏少。基线低HBsAg定量及治疗过程中的动态下降是目前公认的预测HBsAg阴转的最佳指标，其他的因素如病毒基因型、治疗过程中的转氨酶升高、免疫细胞功能及细胞因子水平、宿主因素等均可以影响HBsAg阴转，现就HBsAg阴转的相关指标及潜在预测因子进行综述。.
Keywords: Chronic hepatitis B; Clinical cure; Hepatitis B surface antigen; Predictor.